Treatment Protocol for Use of Anascorp™ in Patients With Scorpion Sting Envenomation

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

1,426

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

September 30, 2010

Study Completion Date

September 30, 2010

Conditions
Scorpion Sting Envenomation
Interventions
DRUG

Antivenin Centruroides (scorpion) F(ab)2 Anascorp™

three vials diluted in 20 to 50 mL normal saline administered intravenously. Subsequent single vial doses of Anascorp, up to a total of five vials administered at thirty minutes intervals until resolution of symptoms.

Trial Locations (18)

85008

Maricopa Medical Center, Phoenix

85016

Phoenix Children's Hospital, Phoenix

85027

John C. Lincoln, Phoenix

85222

Casa Grande Regional Medical Center, Casa Grande

85224

Chandler Regional, Chandler

85260

Southeast Arizona Medical Center, Douglas

Scottsdale Healthcare, Scottsdale

85297

Mercy Gilbert Medical Center, Gilbert

85306

Banner Thunderbird Medical Center, Glendale

85540

Gila Health Resources, Morenci

85546

Mt. Graham Regional Medical Center, Safford

85550

San Carlos Indian Hospital, San Carlos

85621

Holy Cross Hospital, Nogales

85712

Tucson Medical Center, Tucson

85724

University Medical Center, Tucson

85745

St. Mary's Hospital, Tucson

85941

Whiteriver IHS Hospital, Whiteriver

86206

Banner Baywood Medical Center, Mesa

All Listed Sponsors
collaborator

University of Arizona

OTHER

lead

Instituto Bioclon S.A. de C.V.

INDUSTRY

NCT00624078 - Treatment Protocol for Use of Anascorp™ in Patients With Scorpion Sting Envenomation | Biotech Hunter | Biotech Hunter